Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next
Brunhilde Wirth, Mert Karakaya, Min Jeong Kye, et al.
Annual Review of Genomics and Human Genetics (2020) Vol. 21, Iss. 1, pp. 231-261
Closed Access | Times Cited: 206

Showing 1-25 of 206 citing articles:

DNA copy number variation: Main characteristics, evolutionary significance, and pathological aspects
Ondrej Pös, Ján Radvánszky, Gergely Buglyó, et al.
Biomedical Journal (2021) Vol. 44, Iss. 5, pp. 548-559
Open Access | Times Cited: 184
Spinal muscular atrophy — insights and challenges in the treatment era
Eugenio Mercuri, Maria Carmela Pera, Mariacristina Scoto, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 12, pp. 706-715
Closed Access | Times Cited: 160
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Katharina Vill, Oliver Schwartz, Astrid Blaschek, et al.
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 140
Spinal Muscular Atrophy: In the Challenge Lies a Solution
Brunhilde Wirth
Trends in Neurosciences (2021) Vol. 44, Iss. 4, pp. 306-322
Closed Access | Times Cited: 136
Challenges and opportunities in spinal muscular atrophy therapeutics
Crystal Jing Jing Yeo, Eduardo F. Tizzano, Basil T. Darras
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 205-218
Closed Access | Times Cited: 21
New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Tai‐Heng Chen
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3297-3297
Open Access | Times Cited: 118
Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance
Melissa C. Keinath, Devin E. Prior, Thomas W. Prior
The Application of Clinical Genetics (2021) Vol. Volume 14, pp. 11-25
Open Access | Times Cited: 102
The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
Ravindra Singh, Eric W. Ottesen, Natalia N. Singh
Neuroscience Insights (2020) Vol. 15
Open Access | Times Cited: 78
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Serena Stanga, Anna Caretto, Marina Boido, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3719-3719
Open Access | Times Cited: 76
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
Sibylle Jablonka, Luisa Hennlein, Michael Sendtner
Neurological Research and Practice (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 52
Newborn Screening for Spinal Muscular Atrophy in New York State
Bo Hoon Lee, Stella Deng, Claudia A. Chiriboga, et al.
Neurology (2022) Vol. 99, Iss. 14
Open Access | Times Cited: 41
Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy
Eric W. Ottesen, Natalia N. Singh, Diou Luo, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 12, pp. 5948-5980
Open Access | Times Cited: 26
Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor
Qing Xie, Xiupeng Chen, Hong Ma, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 4, pp. 945-965
Open Access | Times Cited: 11
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Edmar Zanoteli, Alexandra Prufer de Queiroz Campos Araújo, Michele Michelin Becker, et al.
Arquivos de Neuro-Psiquiatria (2024) Vol. 82, Iss. 01, pp. 001-018
Open Access | Times Cited: 10
Italian Survey on Evolving SMA Care with Disease-Modifying Therapies: A Consensus Workshop on Nutrition, Swallowing, Respiratory and Rehabilitation Care
Stefania Corti, Valeria Sansone, Ilaria Bitetti, et al.
Neuromuscular Disorders (2025), pp. 105278-105278
Open Access | Times Cited: 1
Healthcare Resource Utilization, Economic Burden, and Multi-Level Medical Security System for Individuals with Spinal Muscular Atrophy in Shaanxi Province, China
Mingyue Zhao, Shujiang Ding, Yulong Zhao, et al.
Healthcare (2025) Vol. 13, Iss. 4, pp. 428-428
Open Access | Times Cited: 1
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy
Elizabeth Kichula, Crystal M. Proud, Michelle A. Farrar, et al.
Muscle & Nerve (2021) Vol. 64, Iss. 4, pp. 413-427
Open Access | Times Cited: 51
RNA Polymerase III Subunit Mutations in Genetic Diseases
Elisabeth Lata, Karine Choquet, Francis Sagliocco, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 49
Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
Harriet Weststrate, Georgia Stimpson, Lily Thomas, et al.
Developmental Medicine & Child Neurology (2022) Vol. 64, Iss. 7, pp. 907-914
Open Access | Times Cited: 32
Newborn Screening for SMA – Can a Wait-and-See Strategy be Responsibly Justified in Patients With Four SMN2 Copies?
Astrid Blaschek, Heike Kölbel, Oliver Schwartz, et al.
Journal of Neuromuscular Diseases (2022) Vol. 9, Iss. 5, pp. 597-605
Closed Access | Times Cited: 29
Mitochondrial Dysfunction in Spinal Muscular Atrophy
Eleonora Zilio, Valentina Piano, Brunhilde Wirth
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10878-10878
Open Access | Times Cited: 29
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Tommaso Nuzzo, Rosita Russo, Francesco Errico, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 21
Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples
Megi Meneri, Elena Abati, Delia Gagliardi, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1254-1254
Open Access | Times Cited: 17
Sex Difference in Spinal Muscular Atrophy Patients – are Males More Vulnerable?
Jianli Sun, Melissa A. Harrington, Ben Porter
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 5, pp. 847-867
Open Access | Times Cited: 17
A super minigene with a short promoter and truncated introns recapitulates essential features of transcription and splicing regulation of the SMN1 and SMN2 genes
Eric W. Ottesen, Joonbae Seo, Diou Luo, et al.
Nucleic Acids Research (2024) Vol. 52, Iss. 7, pp. 3547-3571
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top